ClinicalTrials.gg
RecruitingNCT06979752Updated Sep 30, 2026

Efficacy and Safety of Tran Cannula in Combined Pseudoexfoliative Glaucoma and Cataract Surgery Compared With Augmented Ocular Irrigation

An interventional study of Tran canula and augmented irrigation in Glaucoma, Open Angle, Pseudo-exfoliative and Cataract, sponsored by Hôpital Privé de la Baie. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Hôpital Privé de la Baie · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Sep 30, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Glaucoma with a site in France — 10 open to participants now, 11 under way, none of them phase 3. Glaucoma · France.

Planned enrollment
22nd of 38
58 · median 105
Started
2025
with 2 others
No phase
29 of 54
7 open now
Primary completion
2028-02
later than 7 of 10 live
Registered
51st of 54
by date
Lead sponsor
4 of 54
Hôpital Privé de la Baie

Among the 54 studies in Glaucoma with a site in France, this one is the 22nd largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2025, is one of 29 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 51st registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

10 of the 54 studies in Glaucoma with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Glaucoma with a site in France, or all of them as a file.
02

Study summary

Pseudoexfoliative glaucoma is a glaucoma secondary to pseudoexfoliative syndrome; cataract surgery is often more difficult, with more complications. Tran's cannula is a single-use irrigation system designed for cleaning, with the pseudoexfoliative material remaining in the trabecular meshwork.

The main objective of this study is to evaluate the efficacy of the Tran cannula, in comparison with increased irrigation, in lowering intraocular pressure (IOP) in patients with pseudoexfoliative glaucoma and treated for glaucoma, and with an indication for isolated cataract surgery.

03

Conditions studied

  • Glaucoma, Open Angle, Pseudo-exfoliative
  • Cataract
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with cataract and early-to-moderate pseudoexfoliative glaucoma (GPX) scheduled for isolated cataract surgery.
  • Reliable visual field, Humphrey 24-2, Sita-Fast, with typical glaucoma alterations, and with mean deviation ≤-12 dB.
  • OCT with ganglion cell alterations and fibers typical of glaucoma.
  • Typical glaucomatous neuropathy
  • Slit-lamp signs of pseudoexfoliation.
  • Open angle (2 to 4, according to Shaffer classification) determined by gonioscopy.
  • Untreated eye pressure >21 mmHg and \<33 mmHg

Exclusion criteria

Exclusion Criteria:

  • Presence of other ophthalmological pathologies (except cataract or mild dry eye)
  • History of intraocular surgery in the last 12 months, history of trauma
  • History of laser trabeculoplasty (TLA or SLT) in the previous 12 months
  • Visual acuity below "finger count
  • Myopia ≥ 6 dioptres, hyperopia ≥ 5 dioptres
  • Iridocorneal angle closure (and angle-closure glaucoma), any other type of non-pseudoexfoliative glaucoma, iris neovascularization
  • Pachymetry \< 490 μm or > 620 μm; or corneal pathology or other condition that makes accurate IOP measurements with flattening tonometry, ultrasonic pachymetry or specular microscopy impossible.
  • Presence of severe systemic pathologies
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Tran cannula surgery

    Patients treated with Tran cannula

    Procedure: Tran canula

  • Active comparator
    augmented irrigation surgery

    Patients treated with augmented irrigation cannula.

    Procedure: augmented irrigation

Interventions

  • ProcedureTran canula

    After phacoemulsification, implantation of the intraocular implant and aspiration of the viscoelastic, we connect the TranCanula® to the irrigation system. Then we treat the trabecular mesh.

  • Procedureaugmented irrigation

    After phacoemulsification, We use the classical aspiration cannula to irrigate the trabecular mesh.

06

What researchers measure

Primary outcomes

  1. Intraocular pressure measure

    Time frame: day 1, day 30, month 3, month 6 and month 12 after surgery

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Feb 2028, 31 months after the start.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 31 months is close to that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
May 20, 2025
StartActual
Jun 4, 2025
Primary completionEst.
Feb 2, 2028
CompletionEst.
Feb 2, 2029
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Fondation Rothschild is now Active, not recruiting
Sep 30, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Fondation Rothschild · Paris, FranceContact removed a•••@gmail.com · •••2885
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Fondation Rothschild is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Fondation Rothschild · Paris, FranceContact removed a•••@gmail.com · •••2885
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06979752
Lead sponsor
Hôpital Privé de la Baie
Responsible party
Sponsor
First posted
May 20, 2025
Start date
Jun 4, 2025
Primary completion
Feb 2, 2028 (estimated)
Completion
Feb 2, 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Ana Miguel, MD
Contact
myworld_ana@hotmail.com
+33 7 87 01 61 87

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion